Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
BIRC5 332 ARSENIC TRIOXIDE CHEMBL1200978 NCI 15587394, 16950207
BIRC5 332 CALCITONIN CHEMBL359713 NCI 16222118
BIRC5 332 FLUTAMIDE CHEMBL806 NCI 15735703
BIRC5 332 REGRAMOSTIM CHEMBL2107881 NCI 16403261
BIRC5 332 IMATINIB CHEMBL941 NCI 16254145
BIRC5 332 PACLITAXEL CHEMBL428647 ClearityFoundationBiomarkers, NCI 15347474, 16211241
BIRC5 332 (7S)-HYDROXYL-STAUROSPORINE CHEMBL574737 NCI 15255949
BIRC5 332 DACTINOMYCIN CHEMBL1554 NCI 15883285
BIRC5 332 SULINDAC CHEMBL15770 NCI 16707021, 16950207
BIRC5 332 DEXAMETHASONE CHEMBL384467 NCI 16787583
BIRC5 332 GATAPARSEN (CHEMBL2219774) CHEMBL2219774 antisense oligonucleotide TALC, TdgClinicalTrial, DrugBank
BIRC5 332 TRETINOIN CHEMBL38 NCI 14587026, 16403261, 11939262
BIRC5 332 PLICAMYCIN CHEMBL1237054 NCI 17124180
BIRC5 332 MYCOPHENOLIC ACID CHEMBL866 NCI 15571295
BIRC5 332 TRASTUZUMAB CHEMBL1201585 NCI, CIViC 16452223, 23204226
BIRC5 332 VALDECOXIB CHEMBL865 NCI 16707021
BIRC5 332 TERAMEPROCOL CHEMBL90983 inhibitor TTD
BIRC5 332 ROFECOXIB CHEMBL122 NCI 16707021, 14627349
BIRC5 332 RESVERATROL CHEMBL165 NCI 14729643, 15837718, 17270149
BIRC5 332 VORINOSTAT CHEMBL98 NCI 16951239
BIRC5 332 IRINOTECAN CHEMBL481 NCI 15956246
BIRC5 332 ERLOTINIB CHEMBL553 NCI 17047074
BIRC5 332 PROXYPHYLLINE CHEMBL37390 NCI 12895357
BIRC5 332 INTERFERON BETA-1A CHEMBL1201562 NCI 12117359
BIRC5 332 DOCETAXEL CHEMBL92 ClearityFoundationBiomarkers
BIRC5 332 PHENYLTHIOUREA CHEMBL263376 CIViC 24961465
BIRC5 332 CHLORFENSON CHEMBL499017 NCI 16889755
BIRC5 332 CARBOPLATIN CHEMBL1351 NCI 15347474
BIRC5 332 EPIRUBICIN CHEMBL417 NCI 16608080
BIRC5 332 ROMIDEPSIN CHEMBL1213490 NCI 14767553
BIRC5 332 CYTARABINE CHEMBL803 NCI 14713572
BIRC5 332 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 12118374
BIRC5 332 LONAFARNIB CHEMBL298734 NCI 15090542
BIRC5 332 STAUROSPORINE CHEMBL388978 NCI 17255535
BIRC5 332 SEPANTRONIUM BROMIDE CHEMBL2105734 inhibitor TALC
BIRC5 332 CAMPTOTHECIN CHEMBL65 NCI 16211302
BIRC5 332 LAPATINIB CHEMBL554 NCI 16452223
BIRC5 332 OMACETAXINE MEPESUCCINATE CHEMBL46286 NCI 15854289
BIRC5 332 METHOTREXATE CHEMBL34259 NCI 15670151
BIRC5 332 FLUOROURACIL CHEMBL185 NCI 15067352
BIRC5 332 PRASTERONE CHEMBL90593 NCI 16461558
BIRC5 332 EPOETIN ALFA CHEMBL1201565 NCI 17112829
BIRC5 332 GENISTEIN CHEMBL44 NCI 17375591
BIRC5 332 INDOMETHACIN CHEMBL6 NCI 17270149
BIRC5 332 DOXORUBICIN CHEMBL53463 NCI 16211302
BIRC5 332 CHEMBL35482 CHEMBL35482 NCI 11313272
BIRC5 332 PLEVITREXED CHEMBL126648 NCI 14695155

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
BIRC5 rs9904341 CG methotrexate efficacy yes Authors state this significance is marginal and only in the multivariate model not the univariate model after 6 months of treatment. Response was binned into three groups (good, moderate, poor) based on DAS28 score and DAS28 improvement after 6 months. CC vs GG was looked at separately and was not significant. Genotype CG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. 26651826 1447676212